Drug Approval | September 15, 2023
Strides receives tentative USFDA approval for Dolutegravir tablets
The products will be manufactured at the company's facility in Bengaluru
The products will be manufactured at the company's facility in Bengaluru
This advanced technology is specifically tailored for individuals with high power prescriptions, aiming to free the 18-35 age group from the reliance on eyeglasses
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
The products will be manufactured at the company's facility in Bengaluru
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
The company will develop and produce premixes for human nutrition applications
This approval has come from the company's finished dosage form manufacturing facility
Erythromycin tablets is used to prevent and treat infections in many different parts of the body
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
The approval bolsters the company's Mycophenolate Mofetil portfolio
Subscribe To Our Newsletter & Stay Updated
